# 64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab

> **NCT01006226** · NA · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** 64Cu-ATSM PET

## Key facts

- **NCT ID:** NCT01006226
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to funding issues
- **Last updated:** 2013-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006226, "64CuATSM and Hypoxia in Stage IV Non-small Cell Lung Cancer With Carboplatin, Paclitaxel, and Bevacizumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01006226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*